Cargando…

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy

BACKGROUND: Response after peptide receptor radionuclide therapy (PRRT) can be evaluated using anatomical imaging (CT/MRI), somatostatin receptor imaging ([(68)Ga]Ga-DOTA-TATE PET/CT), and serum Chromogranin-A (CgA). The aim of this retrospective study is to assess the role of these response evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huizing, Daphne M. V., Aalbersberg, Else A., Versleijen, Michelle W. J., Tesselaar, Margot E. T., Walraven, Iris, Lahaye, Max J., de Wit–van der Veen, Berlinda J., Stokkel, Marcel P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418334/ https://www.ncbi.nlm.nih.gov/pubmed/32778165 http://dx.doi.org/10.1186/s40644-020-00335-w

Ejemplares similares

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
por: de Vries–Huizing, Daphne M. V., et al.
Publicado: (2021)

Post-PRRT scans: which scans to make and what to look for
por: Aalbersberg, Else A., et al.
Publicado: (2022)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Somatostatin receptor saturation after administration of high peptide amounts of [(177)Lu]Lu-HA-DOTATATE: when enough is enough
por: Siebinga, Hinke, et al.
Publicado: (2022)

Multicentre quantitative (68)Ga PET/CT performance harmonisation
por: Huizing, Daphne M. V., et al.
Publicado: (2019)

The consequences of a new software package for the quantification of gated-SPECT myocardial perfusion studies
por: van der Veen, Berlinda J., et al.
Publicado: (2010)

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions
por: van der Veen, Berlinda J., et al.
Publicado: (2012)

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
por: Siebinga, Hinke, et al.
Publicado: (2022)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy
por: Ebbers, Sander C., et al.
Publicado: (2022)

Ventricular dyssynchrony assessed by gated myocardial perfusion SPECT using a geometrical approach: a feasibility study
por: van der Veen, Berlinda J., et al.
Publicado: (2011)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Improved Quality of Life in Patients Treated with Peptide Radionuclides
por: Traub-Weidinger, T, et al.
Publicado: (2011)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
por: Chakraborty, Kushal, et al.
Publicado: (2023)

Deterioration of Intended Target Volume Radiation Dose Due to Anatomical Changes in Patients with Head-and-Neck Cancer
por: Hamming-Vrieze, Olga, et al.
Publicado: (2021)

An indium-111-labelled membrane-targeted peptide for cell tracking with radionuclide imaging
por: Pruller, Johanna, et al.
Publicado: (2022)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer
por: Huynh, Truc T., et al.
Publicado: (2022)

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

Predicting the effect of different folate doses on [(68)Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

A Peptide Meets a Radionuclide to Combat a Rare Tumor
por: Thomas, Katharine E., et al.
Publicado: (2021)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
por: Yun, Jenny S W, et al.
Publicado: (2022)

Early differences in dynamic uptake of (68)Ga-PSMA-11 in primary prostate cancer: A test-retest study
por: olde Heuvel, J., et al.
Publicado: (2021)

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019)

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor
por: Häfliger, Simon, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
por: Cimini, Andrea, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

The production of radionuclides for the biosciences
por: Ruth, T J
Publicado: (1992)

Radionuclide production for the biosciences
por: Ruth, T J
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_d5sq02767p9iljfhcaifvs9e1p